Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03638921
Other study ID # 35RC17_8826_NEPHROPAIN Après
Secondary ID 2018-001652-3520
Status Completed
Phase Phase 2
First received
Last updated
Start date October 1, 2018
Est. completion date June 1, 2019

Study information

Verified date November 2019
Source Rennes University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

MEOPA (Equimolar Oxygen-Nitrogen Protoxide Mix) is a gas used in emergencies for short-term painful acts. It is often very effective with an analgesic, anxiolytic and muscle relaxant action. It is often combined with other analgesic medicines. It has already been proven in emergency medicine for short-term pain and trauma. It seems that it could be used more particularly for pains of medical origin. A study has already proved its effectiveness in the treatment of migraines in emergencies. The first phase of the NEPHROPAIN study began in 2016 after a favorable opinion from the Regional Ethics Committee. NEPHROPAIN phase AVANT was a prospective non-interventional study on the use of analgesic drugs in nephritic colic in emergencies by Dr. Alexandre Tanneau. This study was conducted at the University Hospital of Rennes and included 60 patients admitted to the emergency department for suspected renal colic. It made it possible to recruit the control group of the NEPHROPAIN study. Its main objective was to describe the suspected population of renal colic in Rennes emergencies, to determine NEPHROPAIN's primary endpoint and the number of NEPHROPAIN needed subjects.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date June 1, 2019
Est. primary completion date June 1, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria :

- Age greater than or equal to 18,

- Presenting a suspicion of renal colic, that is to say a pain at the level of a lumbar fossa radiating towards the external genital organs, of rapidly progressive, non-febrile appearance,

- Having given free, informed and written consent,

- Affiliated to the social security system.

Exclusion Criteria :

- Patient in shock of all types, defined here as an acute cardio-circulatory failure with mean arterial pressure less than 65 mm Hg.

- Oxygen saturation below 93% in ambient air,

- With suspicion of pneumothorax,

- Having a history of emphysema and / or COPD (chronic obstructive pulmonary disease),

- Contraindications to the administration of MEOPA: Patients requiring ventilation in pure oxygen; Intracranial hypertension (headache associated with jet vomiting); Any alteration of the state of consciousness, preventing the cooperation of the patient (Glasgow score less than 15); Head trauma; Pneumothorax; Emphysema bubbles; Gas embolism; Diving accident; Abdominal gas distension; Patient who has recently received an ophthalmic gas (SF6, C3F8, C2F6) used in ocular surgery as long as a gas bubble persists inside the eye and at least for a period of 3 months; Known and unsubstituted deficiency of vitamin B12 or folic acid; Neurological abnormalities of recent appearance and unexplained)

- Contraindication to NSAIDs,

- Patient treated in the long course by analgesic stage 3,

- Pregnant or lactating woman,

- Concomitant participation in another research involving the interventional or minimal risk and minimal human person,

- Major persons subject to legal protection (legal safeguards, guardianship, tutorship) and persons deprived of their liberty.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
MEOPA
Patients included in the study will receive MEOPA with a high concentration mask (bottle stored for at least 48 hours horizontally) at a minimum flow rate of 10 L / min under supervision of a health care worker after explanation of use to the patient in a quiet environment (box). MEOPA will be administered for a maximum total duration of 20 minutes, continuously or not depending on the needs of the patient, but after a continuous phase at the beginning of treatment of at least 3 minutes.

Locations

Country Name City State
France Rennes University Hospital Rennes

Sponsors (2)

Lead Sponsor Collaborator
Rennes University Hospital Fondation Apicil

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Numerical Rating Scale (NRS) Pain Ealuation. Score : 0 to 10. Proportion of individuals whose initial pain evaluation (Digital Scale) is divided by at least two to T20. 20 minutes
Secondary Analgesics consumption Proportion of individuals who used analgesics between T0 and T20, between T20 and T60, between T60 and T240, and between T240 and at the end of hospitalization. 0, 20, 60, 240 minutes and through hospitalization completion (an average of a few hours)
Secondary Adverse effects related to taking analgesics, through treatment completion, an average of a few hours
Secondary NRS average Pain average (digital scale) at T0 (before administration of the first analgesic, MEOPA or other), T20, T60, T240, and at at the end of hospitalization.
Average of NRS score (pain evaluation, score : 0 to 10).
0, 20, 60, 240 minutes and through hospitalization completion (an average of a few hours)
Secondary Hospitalization time Hospitalization time in emergency through hospitalizationcompletion, an average of a few hours
See also
  Status Clinical Trial Phase
Withdrawn NCT01685658 - Intravenous Paracetamol Versus Ketoprofen When Treating Renal Colic in Emergency Situations Phase 4
Completed NCT01349244 - Hydronephrosis on Ultrasound With CT Finding in Patients With Renal Colic N/A
Recruiting NCT04169555 - "Point of Care" Ultrasound and Renal Colic N/A
Completed NCT04160520 - Pramipexole and Morphine for Renal Colic Phase 1/Phase 2
Not yet recruiting NCT04080973 - Metabolic Workup in Patients Suffering From Kidney Stone Disease and Osteopenia N/A
Completed NCT01979042 - Urinary Markers for Unilateral Kidney Obstruction N/A
Completed NCT03865004 - Combination Trial of Intravenous Paracetamol - Morphine for Treating Acute Renal Colic in Emergency Setting: An Optimum Treatment Phase 4
Completed NCT03706404 - Renal Colic Fast Track Pathway in the Emergency Department. N/A
Completed NCT03665753 - Comparison of IV 10, 20, and 30mg for Renal Colic Pain in the ED Early Phase 1
Not yet recruiting NCT05150899 - Role of Antihistaminic in Acute Renal Colic Prevent Pain Recurrence and Expulsion of Ureteric Stone ≤ 1cm
Recruiting NCT03790514 - Heat Wrap for Renal Colic N/A
Completed NCT00646061 - Pain Control in Renal Colic Phase 1
Completed NCT05653401 - Treatment of Renal Colic in the Emergency Department: Comparison Between Magnesium Sulfate and Lidocaine. Phase 2
Not yet recruiting NCT02782273 - Morphine Versus Ketorolac in Renal Colic Phase 4
Completed NCT01352676 - Limit Computed Tomography (CT) Scanning in Suspected Renal Colic
Not yet recruiting NCT06412900 - Radiomics and Image Segmentation of Urinary Stones by Artificial Intelligence
Not yet recruiting NCT06342648 - Intracutaneous Sterile Water and Diclofenac Sodium Injections in Renal Colic N/A
Recruiting NCT03137498 - Lidocaine vs Ketorolac for Management of Renal Colic in the Emergency Department Phase 4
Recruiting NCT01742689 - Analgesic Efficacy of Intranasal Desmopressin in Acute Renal Colic Phase 3
Completed NCT01323842 - Emergency Department Ultrasound in Renal Colic N/A